{
    "xml": "<topic id=\"PHP96719\" outputclass=\"drug\" rev=\"1.16\" type=\"drug\" namespace=\"/drugs/epoetin-alfa\" basename=\"epoetin-alfa\" title=\"EPOETIN ALFA\">\n<title>EPOETIN ALFA</title>\n<body>\n<data name=\"vtmid\">108964008</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_871130604\" title=\"Epoetins\">Epoetins</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34585\" title=\"EPOETINS\" namespace=\"/drug-classes/epoetins\">EPOETINS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n</body>\n<topic id=\"PHP96735\" outputclass=\"pregnancy\" parent=\"/drugs/epoetin-alfa\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>No evidence of harm.</p>\n<p>Benefits probably outweigh risk of anaemia and of blood transfusion in pregnancy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP96725\" outputclass=\"breastFeeding\" parent=\"/drugs/epoetin-alfa\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Unlikely to be present in milk.</p>\n<p>Minimal effect on infant.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP96732\" outputclass=\"hepaticImpairment\" parent=\"/drugs/epoetin-alfa\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturers advise caution in chronic hepatic failure.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP96747\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.8\" parent=\"/drugs/epoetin-alfa\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Products containing epoetin alfa are not identical and although there should be no important differences in terms of safety and efficacy, when prescribing biological products it is good practice to use the brand name.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP96746\" outputclass=\"nationalFunding\" rev=\"1.30\" parent=\"/drugs/epoetin-alfa\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA323</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (November 2014)</p>\r\n<p>Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy.</p>\r\n<p>If different erythropoiesis-stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA323\">www.nice.org.uk/TA323</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP96719-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/epoetin-alfa\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP96831\" title=\"Solution for injection\" namespace=\"/drugs/epoetin-alfa/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34585\" namespace=\"/drug-classes/epoetins\" title=\"EPOETINS\" count=\"1\" rel=\"link\">EPOETINS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP96831\" namespace=\"/drugs/epoetin-alfa/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP96719",
    "outputclass": "drug",
    "rev": "1.16",
    "type": "drug",
    "namespace": "/drugs/epoetin-alfa",
    "basename": "epoetin-alfa",
    "title": "EPOETIN ALFA",
    "vtmid": "108964008",
    "drugClassification": [
        "Epoetins"
    ],
    "inheritsFromClass": [
        "EPOETINS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "No evidence of harm.\n\nBenefits probably outweigh risk of anaemia and of blood transfusion in pregnancy.",
                "html": "<p>No evidence of harm.</p><p>Benefits probably outweigh risk of anaemia and of blood transfusion in pregnancy.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Unlikely to be present in milk.\n\nMinimal effect on infant.",
                "html": "<p>Unlikely to be present in milk.</p><p>Minimal effect on infant.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturers advise caution in chronic hepatic failure.",
                "html": "<p>Manufacturers advise caution in chronic hepatic failure.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Products containing epoetin alfa are not identical and although there should be no important differences in terms of safety and efficacy, when prescribing biological products it is good practice to use the brand name.",
                "html": "<p>Products containing epoetin alfa are not identical and although there should be no important differences in terms of safety and efficacy, when prescribing biological products it is good practice to use the brand name.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA323",
                        "label": "www.nice.org.uk/TA323"
                    }
                ],
                "fundingIdentifier": "NICE TA323",
                "textContent": "Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (November 2014) Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy. If different erythropoiesis-stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used.\n\nwww.nice.org.uk/TA323",
                "html": "<p outputclass=\"title\">Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (November 2014)</p> <p>Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy.</p> <p>If different erythropoiesis-stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA323\">www.nice.org.uk/TA323</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP96831",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "drugClass": [
            {
                "id": "PHP34585",
                "label": "EPOETINS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP96831",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}